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To evaluate the relationship between inflammatory markers and is due to IkB phosphorylation, polyubiquitinylation, and
severity of asthma in children, the amount of interleukin-8 (IL-8) rapid degradation by proteasome. As a result, NF-B translo-
and granulocyte/macrophage colony-stimulating factor (GM-CSF) cates to the nucleus and activates transcription of target genes,
released by peripheral blood mononuclear cells, exhaled nitric oxide increasing the expression of inflammatory mediators (11).
(FE NO) levels, p65 nuclear factor-B subunit, and phosphorylated Among them, granulocyte/macrophage colony-stimulating fac-
IkB expression by peripheral blood mononuclear cells were assessed tor (GM-CSF) and interleukin-8 (IL-8) have been shown to
in six control subjects, 12 steroid-naives subjects with intermittent play an important role in asthma, and in particular in persistent
asthma, and 17 children with moderate asthma. To investigate their severe asthma (12, 13). Inflammation in the airways can also
predictive value, biomarker levels were correlated with the number be reflected by the levels of nitric oxide in exhaled air (FE
of exacerbations during a 18-month follow-up period. We found that NO) (14).
GM-CSF release was higher in moderate and intermittent asthmat- Glucocorticosteroids are powerful antiinflammatory drugs,ics than in control subjects, whereas IL-8 release was higher in
which by interacting with transcription factors such as NF-B,moderate than in intermittent asthmatics and control subjects. FE
repress the activation of proinflammatory genes (15). InhaledNO levels were similar among study groups. In moderate asthmat-
corticosteroids represent the best treatment of asthma. How-ics, IL-8, GM-CSF, and FE NO significantly correlated with the exacer-
ever, at recommended doses, although they usually controlbation numbers. Moreover, p65 and phosphorylated IkB levels
symptoms and improve lung function, they have an incompletewere greater in moderate than in intermittent asthmatics and con-
efficacy on airway inflammation and bronchial hyperrespon-trol subjects. According to GM-CSF, IL-8, and FE NO levels, two
siveness (16). To evaluate the relationship between minimallydistinct subgroups of moderate asthmatics (low and high produc-
invasive markers of airway inflammation with asthma severityers) were identified. High producers experienced more exacerba-
tions than low producers. This study shows ongoing inflammation in children, we undertook a pilot study in which the release
associated with biological and clinical heterogeneity in moderate of IL-8 and GM-CSF by peripheral blood mononuclear cells
asthmatics despite regular treatment and proposes that large pro- (PBMC), as well as the levels of FE NO, were assessed at
spective studies confirm the importance of biomarkers to assess study entry in children with intermittent and moderate asthma
inflammation and asthma control in children with asthma. who were clinically well controlled and receiving high doses
of inhaled corticosteroids and long-acting 2 agonists. We then
Keywords: asthma; inflammatory markers; fluticasone propionate examined whether the in vitro production of IL-8 and GM-
CSF by these cells was sensitive to pyrrolidinedithiocarbamate,The identification of biomarkers measured using non- or mini-
an inhibitor of NF-B activation (17). Finally, to better charac-mally invasive methods represents an important goal in the
terize the activation of NF-B pathway, we analyzed the ex-management of childhood asthma for several reasons. First,
pression of p65 NF-B subunit and of the phosphorylatedinflammatory and structural changes of the airways occur very
form of IkB (p-IkB) in PBMC of the study groups. Finally,early in asthma; second, the long-term management of child-
the biological parameters examined were correlated with thehood asthma is still debated (1–3); third the risk/benefit ratio
number of exacerbations occurring during a follow-up periodof a prolonged treatment with high steroid doses can be prob-
of 18 months.lematic (4–6); fourth, clinical subpopulations exist in children
with severe asthma (7). The persistence of airway inflammation
METHODSin asthma is likely to be due to the sustained transcription and
production of inflammatory mediators. Among transcription Subjects
factors, nuclear factor-B (NF-B) plays an important role in
Twenty-nine asthmatics (6–14 years, mean  SD: 9.6  2.3) were re-airway inflammation (8–10) and activates the transcription of
cruited from an outpatient clinic. The diagnosis of asthma and theseveral genes. NF-B activation is inhibited by endogenous
assessment of its severity were done at study entry according to Globalcytoplasmic inhibitors, known as IkBs. The most characterized Initiative for Asthma 1995 (18). Twelve children had intermittent asthma,
NF-B inhibitor is IkB, which binds avidly to the p65 (RelA) treated with short-acting 2 agonists on demand during the last 6
subunit of NF-B, precluding its nuclear translocation and months preceding the study; 17 children had moderate persistent
transcriptional activity. The dissociation of IkB from NF-B asthma, treated with fluticasone propionate 250 mg (inhaler device
Diskus [GlaxoSmithKline, London, UK]) plus salmeterol 50 g twice
daily for at least 6 months before their inclusion in the study. The
control group consisted of six healthy children (7–11 years, mean 
SD: 9.5  1.3). The study was approved by our local ethics committee,(Received in original form June 12, 2002; accepted in final form January 28, 2003)
and written consent was obtained from parents.
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and specific IgE to aeroallergens commonly present in the Palermo were quantified by enzyme-linked immunosorbent assay (R&D Systems,
Oxon, UK) after the end of the study.area. The compliance to the therapy was assessed by checking the inha-
lation technique at every visit. We also measured in the three study
Nitric Oxide Measurementgroups basal plasma cortisol concentration at 8:00 a.m. (22, 23) by elec-
trochemiluminescence (24), at study entry and at the end of the follow- FE NO was determined by chemiluminescence (Sievers Instruments
up period. Results were expressed in nanomolar concentrations, and Inc, Boulder, CO, USA) and measured in triplicate after fast inhalation
adherence was considered satisfactory if cortisol was less than 100 nM. maneuvers to total lung capacity, at a constant expiratory flow of 100 ml/
seconds against an expiratory resistance of 20 cm water (25).
Production of Cytokines by PBMC
Western BlottingPBMC isolated by Ficoll-Hypaque gradient centrifugation were cultivated
as described previously (13) in the absence or presence of pyrrolidinedi- Western blot analyses were performed as described previously (13).
thiocarbamic acid. All supernatants were stored at 80C, and cytokines
Study Design
This was a study in which several biomarkers (IL-8 and GM-CSF released
by PBMC, p65 and p-IkB protein level in PBMC, and FE NO) were
measured in 29 children with asthma at study entry; these markers were
then correlated with asthma control assessed longitudinally by the number
of exacerbations during a follow-up period of 18 months. After a month
of run-in period, during which FEV1 before and after bronchodilatation
(400 g of salbutamol) was assessed, patients attended the out-patient
clinic (visit 1) and underwent clinical assessment (pre- and postbronchodi-
lator FEV1) at 3, 6, 12, and 18 months by the same physician (S.L.G.),
who was unaware of the results on biomarker measurements. During
the follow-up period, mild and severe exacerbations were defined, ac-
cording to the Formoterol and Corticosteroids Establishing Therapy
study (26). At the beginning of the study, the parents were instructed to
refer to our center if any exacerbation occurred. Severe exacerbations
were treated with a short course of oral steroids (1 mg/kg of prednisolone
for 5 days).
Statistical Analysis
Nonparametric tests were used.
RESULTS
Patient Characteristics
All asthmatic children were monosensitized to house dust mites
(Table 1). Evidence of satisfactory adherence to therapy was ob-
tained in all but one patient, who was excluded from the follow-
up analysis.
GM-CSF and IL-8 Production
GM-CSF production by PBMC was similar in children with mod-
erate and intermittent asthma and significantly higher than in
children in the control group (p 0.001) (Figure 1A). IL-8 release
by PBMC was higher in childen with moderate asthma than in
children with intermittent asthma and children in the control group
(p  0.002 and p  0.0001, respectively) (Figure 1B).
Figure 1. Release of granulocyte/macrophage colony-stimulating factor
(GM-CSF) and interleukin-8 (IL-8) by peripheral blood mononuclear cells
(PBMC) and levels of exhaled nitric oxide (FE NO). Assessment of the
concentrations of IL-8 (A ) and GM-CSF (B ) released by PBMC and of
levels of FE NO (C ) in eight normal children, 12 children with intermittent
asthma, and 17 children with moderate asthma. Individual data are
shown. Horizontal lines represent the median. Within the moderate asth-
matic group, two distinct subgroups of children were observed according
to the levels of GM-CSF and IL-8: one (low producers) characterised by a
low release of both mediators by PBMC (IL8  1,100 ng/ml; GM-CSF 
19 pg/ml); another subgroup (high producers) characterised by a high
release of both mediators (IL8 	 1,100 ng/ml; GMCSF 	 19 pg/ml).
In the figure, closed triangles show low producers moderate persistent
asthmatics whereas open triangles show high producers moderate persis-
tent asthmatics. Closed circles: child with noncompliant moderate persis-
tent asthma. Statistical analysis and p values were assessed without includ-
ing the noncompliant subject.
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TABLE 1. DEMOGRAPHIC CHARACTERISTICS OF SUBJECTS
p Value
Intermittent Moderate
Controls Asthma Asthma C/IA C/MA IA/MA
Number 6 12 17
Sex, M/F 4/2 12/5 8/4
Age 10 (9–10) 9 (8–10) 9 (8–13) NS NS NS
Total IgE (KU) 20 (15–20) 490 (335–450) 500 (407–600) p  0.02 p  0.001 NS
FEV1 (%) 100 (100–102) 98 (93–105) 96 (89–114) NS NS NS
Asthma duration, yr NA 2 (1–4) 4 (2–6) NS
Exacerbations* 0 1 (1–2) 2 (1.75–3.25) NS
Cortisol (nM)† 346 (215–458) 194 (170–225) 66 (58–95) p  0.001 p  0.0001 p  0.004
Cortisol (nM)‡ 342 (215–447) 195 (170–225) 69 (56–95) p  0.02 p  0.0001 p  0.004
Results are expressed as median and (25–75 percentiles).
* Number of exacerbations over the 18 months of the study.
† Cortisol levels at study entry.
‡ Cortisol levels at the end of the follow-up period (18 months).
asthma and normal children (p65: p  0.001; p-IkB: p  0.003FE NO Measurements
and p  0.002), (Figures 4 and 5). A significant correlation wasThe levels of FE NO were nonsignificantly increased in both
found between IL-8 and GM-CSF levels released by PBMC orchildren with intermittent and moderate asthma in comparison
FE NO and the amount of p-IkB (p  0.006, p  0.005, andwith control subjects (Table 1 and Figure 1).
p  0.02, respectively; Spearman rank test) or p65 (p  0.05, p 
Biological and Clinical Heterogeneity in Children 0.007, and p  0.05, respectively; Spearman rank test).
with Moderate Asthma
Correlation between Biomarkers and Asthma Exacerbations
Two distinct subgroups of children with moderate asthma were
In patients with moderate asthma, there were 39 exacerbationsobserved: low producers, characterized by low mediator release
(mean 2.2 exacerbations per patient), of which 31 were moderate(IL-8  1,100 pg/ml; GM-CSF  19 pg/ml) (Figures 1A and 1B)
and eight severe. Three out of 17 patients did not have anyand low FE NO levels ( 20 ppb) (Figure 1C), and high producers,
exacerbation. IL-8, GM-CSF, and FE NO levels were signifi-characterized by a high mediator release and high FE NO levels
cantly correlated with the number of exacerbations (p  0.004,(IL-8 	 1,100 pg/ml; GM-CSF 	 19 pg/ml; FE NO 	 20 ppb)
p 0.004, and p 0.002) (Figure 6). In addition, high producers(Figures 1A–1C). Pyrrolidinedithiocarbamate treatment inhibited
IL-8 release by 52% for high producers and 32% for low produc- had a significantly higher number of exacerbations (3.2/patient/
ers, and GM-CSF release by 40% for high producers and 24% year) than low producers (1/patient/year) (p 0.002). Moreover,
for low producers (p  0.001) (Figure 2). In high producers (but only high producers experienced severe exacerbations. Likewise,
not in low producers) postbronchodilator FEV1 significantly di- an increased number of exacerbations was observed in three
minished by the end of the study (p  0.005) (Figure 3). children with intermittent asthma who showed increased produc-
tion of IL-8 and GM-CSF by PBMC as well as enhanced FE
Protein Levels of NF-B p65 Subunit and p-IkB Protein
NO levels. Finally, the levels of cortisol were similar in high and
The relative amount of p65 and p-IkB protein was higher in low producers and did not significantly correlate with the levels
children with moderate asthma than in children with intermittent of the biomarkers studied.
DISCUSSION
This study shows that the levels of several biomarkers, such as
IL-8 and GM-CSF released by PBMC as well as NF-B, p-IkB
Figure 3. Mean (95% confidence in-
terval) FEV1 (% of predicted) before
and after bronchodilator in children
with moderate asthma. FEV1 (% of
predicted) was measured at study en-
try (visit 1) and during the follow-up
period at 3 (visit 2), 6 (visit 3), 12 (visit
4), and 18 (visit 5) months. Dotted
lines and solid lines show the changeFigure 2. Effect of in vitro pyrrolidinedithiocarbamate (PDTC) treatment
on IL-8 and GM-CSF release. Concentrations of GM-CSF (A ) and IL-8 of FEV1 in children with asthma, low
and high producers, respectively. In(B ) produced by PBMC isolated from children with moderate persistent
asthma cultivated for 24 hours in the absence or presence of 500 mM high producer children with asthma,
a statistical significant change wasPDTC. Individual data are shown. Horizontal lines represent the medians.
Closed triangles: low producers, children with moderate persistent found comparing postbronchodilator
FEV1 at visit 5 versus visits 2 and 3asthma. Open triangles: high producers, children with moderate persis-
(asterisk). (p  0.005, by analysis oftent asthma. Closed circles: children with noncompliant moderate persis-
tent asthma. Statistical analysis and p values were assessed without variance with Bonferroni’s correction). The results are expressed as mean
(95% confidence interval) FEV1 before and after bronchodilator.including the noncompliant subject.
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Figure 4. p65 protein expression in PBMC of normal children and chil- Figure 5. p-IkB protein expression in PBMC of normal children, chil-
dren with intermittent and moderate asthma. (A ) Representative West-dren with intermittent and moderate asthma. (A ) Representative Western
blot analysis of p65 in PBMC from two normal children (lanes 2 and 3 ), ern blot analysis of p-IkB in PBMC from two normal children (lanes 2
and 3 ), three children with intermittent asthma (lanes 4, 5, and 6 ),three children with intermittent asthma (lanes 4, 5, and 6 ), and three
children with moderate asthma (lanes 7, 8, and 9 ). In lane 1, 5 mg of and three children with moderate asthma (lanes 7, 8, and 9 ). In lane
1, 5 mg of total protein from A549 cells were loaded on the gel astotal protein from A549 cells were loaded on the gel as reference for p65
expression. (B ) The same blot was probed with a monoclonal antibody reference for p-IkB expression. (B ) The same blot was probed with a
monoclonal antibody directed against Hsp90. (C ) Signals correspondingdirected against Hsp90. (C ) Signals corresponding to p65 on the various
Western blots were semiquantified by densitometric scanning and nor- to p-IkB on the various Western blots were semiquantified by densito-
metric scanning and normalized relatively to the amount of p-IkB inmalized relatively to the amount of p65 in A549 cells. Horizontal lines
represent the medians. Closed triangles: low producers, children with A549 cells. Horizontal lines represent the medians. Closed triangles: low
producers moderate persistent asthmatics. Open triangles: high produc-moderate persistent asthma. Open triangles: high producers, children with
moderate persistent asthma. Closed circles: children with noncompliant ers moderate persistent asthmatics. Closed circles: children with non-
compliant moderate persistent asthma. Statistical analysis and p valuesmoderate persistent asthma. Statistical analysis and p values were assessed
without including the noncompliant subject. were assessed without including the noncompliant subject.
and FE NO, are significantly higher in children with intermittent likely that a number of these patients may fall into the category
and moderate persistent asthma than in healthy control children. of “steroid insensitive” because despite the high dose of inhaled
In addition, this study suggests that two different subgroups of corticosteroid they are still having relapses and require courses
children with moderate asthma can be identified according to the of oral corticosteroid.
levels of biomarkers measured. Although inhaled corticosteroids This study also shows that in some patients, at recommended
are highly effective in children with asthma, some patients are doses, inhaled corticosteroids do not completely inhibit all in-
not fully controlled, probably because of an ongoing inflamma- flammatory cellular and molecular mechanisms underlying air-
tion. We therefore designed this pilot study to assess longitudi- way inflammation. In some patients with moderate persistent
nally asthma control in children with moderate asthma and to
investigate the predictive value of several inflammatory biomark-
ers measured at study entry. In addition, to avoid any bias due
to lack of adherence to treatment, compliance was assessed by
measuring the levels of cortisol (5, 7, 24) in children with both
Figure 6. Correlations between num-intermittent and moderate persistent asthma. Severity was also
ber of exacerbations and levels of in-checked according to Global Initiative for Asthma 1995 guide-
flammatory mediators. Correlationslines to avoid any influence of a misclassification on the parame-
between number of exacerbations andters assessed in the study.
(A) IL-8 release by PBMC isolated fromThis study shows the presence of a persistent inflammation
children with moderate asthma, (B)in children with moderate asthma despite a treatment with high
GM-CSF release by PBMC isolated fromdoses of inhaled corticosteroids. It was possible to identify two
children with moderate asthma, anddistinct subgroups of patients with moderate asthma character-
(C ) FE NO in children with moderateized by high or low levels of inflammatory biomarkers. Patients
asthma. Closed triangles: low produc-of the “high producer” subgroup experienced a greater number
ers, children with moderate persis-
of exacerbations and a greater decline in postbronchodilator tent asthma. Open triangles: high
FEV1 at the end of the study. producers, children with moderate
It is likely that the clear differences in clinical and biological persistent asthma. Closed circles: chil-
parameters between children with intermittent and persistent dren with noncompliant moderate
asthmat reflect the selection of the subjects from two extremes persistent asthma. Statistical analysis
of the asthma spectrum. In fact, patients classified as moderate and p values were assessed without
persistent using the Global Initiative for Asthma 1995 classifica- including the noncompliant subject.
tion should be ascribed to “severe asthmatics” in the new 2002
update of the Global Initiative for Asthma classification. It is also
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asthma, an increased activation of NF-B was demonstrated by by PBMC as well as the levels of NF-B, p-IkB, and FE NO
may be useful to assess clinical heterogeneity in children withthe overexpression of p65 subunit. On inflammatory activation,
IkB is phosphorylated and proteolyzed, resulting in release of moderate asthma. This study also proposes the need to perform
large prospective studies to confirm the importance of measuringNF-B dimers from the cytoplasmic NF-B/IkB complex and
translocation to the nucleus. The de novo synthesis of IkB after peripheral blood markers to assess airway inflammation and
asthma control in children with asthma.degradation inhibits NF-B in the absence of a new signal (27).
Enhanced IkB phosphorylation, observed in some children
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